share_log

Seagen Wins $42M Patent Claim Against Daiichi In Cancer Drug Case

Seagen Wins $42M Patent Claim Against Daiichi In Cancer Drug Case

SeaGen在抗癌药物案中赢得对Daiichi的4200万美元专利索赔
Benzinga Real-time News ·  2022/04/11 09:20

A jury in Marshall, Texas, awarded Seagen Inc (NASDAQ:SGEN) $41.82 million from Daiichi Sankyo Co (OTC:DSNKY) over claims that Daiichi and AstraZeneca plc's (NASDAQ:AZN) breast-cancer drug Enhertu violates Seagen's patent rights.

得克萨斯州马歇尔的陪审团裁定SeaGen公司(纳斯达克：SGEN)4,182万美元第一三共公司(场外交易：DSNKY)就Daiichi和阿斯利康纳斯达克(Sequoia Capital：AZN)治疗乳腺癌的药物恩海图侵犯了西根公司的专利权。

  • The jury found that Daiichi willfully infringed a patent owned by Seagen that covers technology for delivering chemotherapy drugs to cancer cells.
  • Naoto Tsukaguchi, Corporate Officer and General Counsel, Daiichi Sankyo, said in a statement, "Daiichi Sankyo disagrees with the jury verdict, is committed to defending its rights, and will explore options with respect to the jury verdict, including post-trial motions and an appeal."
  • Seagen said it was pleased with the verdict and would request additional royalties on future sales of Enhertu in the U.S. until the patent expires in November 2024.
  • Seagen filed the lawsuit in the U.S. District Court for the Eastern District of Texas in 2020, claiming Enhertu works in the same way as its patent related to antibody-drug conjugates, which use antibodies to target cancer cells with chemotherapy drugs.
  • Price Action: SGEN shares closed 2.74% lower at $151.84 on Friday.
  • 陪审团发现，Daiichi故意侵犯了Seagen拥有的一项专利，该专利涵盖了将化疗药物输送到癌细胞的技术。
  • 三共株式会社社长兼法律总顾问津口直人在一份声明中表示：“三共不同意陪审团的裁决，致力于捍卫自己的权利，并将探索有关陪审团裁决的选择，包括庭审后动议和上诉。”
  • SeaGen表示，它对这一判决感到高兴，并将要求对Enhertu未来在美国的销售收取额外的版税，直到该专利于2024年11月到期。
  • SeaGen于2020年向美国德克萨斯州东区地区法院提起诉讼，声称Enhertu的工作原理与其与抗体-药物结合物相关的专利相同，后者使用抗体通过化疗药物靶向癌细胞。
  • 价格行动：Sgen股价周五收低2.74%，报151.84美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发